Records containing: Multiple Myeloma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-04-08EVALUATION OF CHOLECALCIFEROL (VitD3) MAINTENANCE SUPPLEMENTATION IN PATIENTS WITH MULTIPLE MYELOMA (MM) UNDERGOING TRANSPLANTATION AND IN COMBINATION WITH LENALIDOMIDE MAINTENANCE
-
CLINICAL_TRIALS study record update · 2025-04-06A Single-Center, Open-Label, Single-Arm Clinical Study of Sequential Anti-BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-Eligible Newly Diagnosed Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-04-06CAR-T Cell Therapy Combined With Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-04-06Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis
-
CLINICAL_TRIALS study record update · 2025-04-03A Phase 1 Dose Escalation and Expansion Study of CID-103, an Anti-CD38 Antibody, in Patients With Previously Treated Relapsed or Refractory Multiple Myeloma
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-04-03Detect and Profile Multiple Myeloma Measurable Residual Disease (MRD )Prognostics for Monitoring Post-transplant Multiple Myeloma (MM) Patients Receiving Maintenance Therapy.
-
CLINICAL_TRIALS study record update · 2025-04-03A Prospective Phase 2 Study to Assess the Minimal Residual Disease After Ixazomib Plus Lenalidomide Plus Dexamethasone (IRd) Treatment for Newly Diagnosed Transplant Eligible Myeloma Patients
-
CLINICAL_TRIALS study record update · 2025-03-30A Prospective, Multinational Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMID, and CD38 Monoclonal Antibody Treatment
-
CLINICAL_TRIALS study record update · 2025-03-30Whole Body MRI in Oncology
-
CLINICAL_TRIALS study record update · 2025-03-30Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma. A Phase II Study (Allo-MM-PostCy-Study)
-
CLINICAL_TRIALS study record update · 2025-03-30Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory T(11;14) Multiple Myeloma (Phase I/IIa) the BELI(E)VE-Trial
-
CLINICAL_TRIALS study record update · 2025-03-28A Phase 2 Study of CC220 (Iberdomide) Combined With Low-dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd): ICON Study
-
CLINICAL_TRIALS study record update · 2025-03-28A Randomized Phase II Trial Comparing Stem Cell Mobilization With Chemotherapy and Cytokine (G-CSF) Versus Cytokine (G-CSF) Alone in Myeloma Patients (MOCCCA-trial).
-
CLINICAL_TRIALS study record update · 2025-03-28Multicenter Non-interventional Study to Investigate Drug Utilization of Pomalidomide in Clinical Practice for the Treatment of Relapsed/Refractory Multiple Myeloma (rrMM)
-
CLINICAL_TRIALS study record update · 2025-03-25A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.
-
CLINICAL_TRIALS study record update · 2025-03-25A Randomized Controlled Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma
-
CLINICAL_TRIALS study record update · 2025-03-24A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-92328 in Subjects With Relapsed and/or Refractory Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-03-21China Continuation: A Single-Arm, Open-Label Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
-
CLINICAL_TRIALS study record update · 2025-03-20Isatuximab in Combination With Bortezomib and Lenalidomide With Minimal Dexamethasone in Transplant-ineligible Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-03-20A Phase I Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-03-20The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
-
CLINICAL_TRIALS study record update · 2025-03-18Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe): An Investigator Sponsored Trial
-
CLINICAL_TRIALS study record update · 2025-03-18A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
-
CLINICAL_TRIALS study record update · 2025-03-18MAGNETISMM-1 A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC AND CLINICAL ACTIVITY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) - CD3 BISPECIFIC ANTIBODY, AS A SINGLE AGENT AND IN COMBINATION WITH IMMUNOMODULATORY AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY ADVANCED MULTIPLE MYELOMA (MM)
-
CLINICAL_TRIALS study record update · 2025-03-17A Comparison of Plerixafor/G-CSF With Chemotherapy/G-CSF for Stem Cell Mobilisation